ReNeuron automates stem cell manufacturing process

The UK's ReNeuron Group says a paper has been published in the journal Biotechnology Letters, demonstrating successful automation of the  manufacturing if its ReN001 neural stem cell line for stroke.

The research was conducted in collaboration with the remedi Project at  Loughborough University, UK. ReNeuron's standard cell manufacturing  process was adapted and transferred to an automated system using a  commercially-available robotic cell culture system - the CompacT SelecT  designed and manufactured by The Automation Partnership, an innovative  UK-based company focused on the development of advanced automated  systems for the global life sciences market. With minor modifications of  the standard process, the robot was programmed to successfully  manufacture a batch of cells. The growth rate and the quality  characteristics were identical to those produced manually.

John Sinden, chief scientific officer of ReNeuron, said: "the successful  automation of our ReN001 manufacturing process heralds two exciting  advances. Firstly, ReNeuron has access to a precise platform allowing  optimization of its cell culture process, leading to lower costs and  increased yield. Secondly, we anticipate that automation will deliver a  more reliable scale of manufacture progressing the therapy into later  stage trials and beyond."